This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Freeline Therapeutics Holdings Toekomstige groei
Future criteriumcontroles 2/6
Freeline Therapeutics Holdings is forecast to grow earnings and revenue by 22.5% and 60.3% per annum respectively while EPS is expected to grow by 69.9% per annum.
Belangrijke informatie
22.5%
Groei van de winst
69.9%
Groei van de winst per aandeel
| Biotechs winstgroei | 34.8% |
| Inkomstengroei | 60.3% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 01 Aug 2023 |
Recente toekomstige groei-updates
Geen updates
Recent updates
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2025 | 26 | -46 | -43 | -28 | 3 |
| 12/31/2024 | N/A | -76 | -72 | -69 | 4 |
| 12/31/2023 | 5 | -55 | -53 | -62 | 4 |
| 3/31/2023 | N/A | -61 | -77 | -70 | N/A |
| 12/31/2022 | N/A | -89 | -85 | -78 | N/A |
| 9/30/2022 | N/A | -101 | -79 | -76 | N/A |
| 6/30/2022 | N/A | -117 | -86 | -83 | N/A |
| 3/31/2022 | N/A | -132 | -102 | -100 | N/A |
| 12/31/2021 | N/A | -140 | -112 | -108 | N/A |
| 9/30/2021 | N/A | -144 | -129 | -124 | N/A |
| 6/30/2021 | N/A | -138 | -136 | -132 | N/A |
| 3/31/2021 | N/A | -115 | -115 | -111 | N/A |
| 12/31/2020 | N/A | -96 | -97 | -95 | N/A |
| 9/30/2020 | N/A | -73 | -73 | -72 | N/A |
| 6/30/2020 | N/A | -63 | -53 | -51 | N/A |
| 3/31/2020 | N/A | -58 | -57 | -54 | N/A |
| 12/31/2019 | N/A | -54 | -55 | -52 | N/A |
| 12/31/2018 | N/A | -33 | -30 | -26 | N/A |
| 9/30/2017 | N/A | -17 | -20 | -19 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: 78F0 is forecast to remain unprofitable over the next 3 years.
Winst versus markt: 78F0 is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: 78F0 is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: 78F0's revenue (60.3% per year) is forecast to grow faster than the German market (4.6% per year).
Hoge groei-inkomsten: 78F0's revenue (60.3% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if 78F0's Return on Equity is forecast to be high in 3 years time